BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALN-ANG3 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALN-ANG3\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06452771-353@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:ALN-ANG3: Phase 1 readout est. (NCT06452771)
DESCRIPTION:ALN-ANG3\, phase 1\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3
  Are Safe and Well Tolerated in Healthy Adults\nEstimated primary completi
 on: 4 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 aln-ang3#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06452771
URL:https://assetmemo.bio/drug/aln-ang3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271186-353@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:ALN-ANG3: Phase 2 readout est. (NCT07271186)
DESCRIPTION:ALN-ANG3\, phase 2\, Chronic Kidney Disease.\nStudy: Study to A
 ssess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney D
 isease\nEstimated primary completion: 13 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aln-ang3#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07271186
URL:https://assetmemo.bio/drug/aln-ang3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
